• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

IDM begins second phase of clinical trials for melanoma vaccine

Article

San Diego--IDM Pharma, based here, has begun phase 2 clinical trials in Europe for its melanoma vaccine Uvidem, which IDM is developing in collaboration with Paris-based pharmaceutical firm Sanofi-Aventis.

San Diego-IDM Pharma, based here, has begun phase 2 clinical trials in Europe for its melanoma vaccine Uvidem, which IDM is developing in collaboration with Paris-based pharmaceutical firm Sanofi-Aventis.

The trial will recruit 50 melanoma patients, 25 of whom will receive Uvidem alone while the remaining 25 will receive Uvidem combined with peginterferon alpha-2b, which has been approved in Europe for the treatment of hepatitis C and is currently under development by Schering-Plough for the treatment of melanoma.

IDM says the primary goal of the trial is to evaluate a specific immune response to the vaccine after treatment with Uvidem, with or without peginterferon alpha-2b. Secondary objectives are safety and disease-free survival.

Plans call for the Europeantrials to be conducted in centers in France, Germany and the United Kingdom. A separate phase 2 trial of Uvidem already is under way in the United States, following positive clinical results in the first stage.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.